Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Publication
, Other
Lampert, EJ; Zimmer, A; Padget, M; Cimino-Mathews, A; Nair, JR; Liu, Y; Swisher, EM; Hodge, JW; Nixon, AB; Nichols, E; Bagheri, MH; Levy, E ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., … Lee, J.-M. (2023). Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. https://doi.org/10.1158/1078-0432.22479107